Extensive consolidation in pharma distribution confined to the retail industry in Russia

6 October 2011

In recent years consolidation on the Russian pharmaceutical distribution market has taken place mostly in the retail, whereas there has been stagnation on the wholesale market. In Ukraine acquisitions in both wholesale and retail pharmaceutical distribution stopped because of the more cautious policies of companies during the crisis, according to the latest report from Poland-based market research firm PMR, titled Distribution on the pharmaceutical market in Russia and Ukraine 2011.

Retail much less concentrated than wholesale

Both the Russian and Ukrainian wholesale pharmaceutical markets are more consolidated than the retail pharmaceutical markets. The share of the top five retail pharmaceutical companies is 10% in Russia and 9% in Ukraine, while for wholesale sectors those percentages reach 70%-80%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >